therapy of children with juvenile idiopathic arthritis. new drug therapy rik joos, m.d. centre for...
TRANSCRIPT
![Page 1: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/1.jpg)
Therapy of children with juvenile idiopathic arthritis. New drug therapy
Rik Joos, M.D.Centre for Paediatric RheumatologyUniversity hospital, Gent, Belgium
![Page 2: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/2.jpg)
JIA – JCA – JRA???
What’s in a name?
![Page 3: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/3.jpg)
J C A – J R A – J I ASystemic Onset
ArthritisHigh spiking feverFugitive rash AdenopathyHepatosplenomegalySerositisNo specific age at onsetBoys = Girls
![Page 4: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/4.jpg)
J C A – J R A – J I APolyarticular Onset
Age at onset: 3-6 and 10 – 14 yearsGirls > or = BoysSymmetrical polyarthritisRapid ankylosis (wrists, neck, feet)Systemic symptoms are possible
![Page 5: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/5.jpg)
J C A – EOPA J R A - OLIGO
J I A – OLIGO
Age at onset 2 - 4 years Girls >>> BoysArthritis of one or both kneesChronic posterior uveitis (30 %)ANA positive (> 80 %)
![Page 6: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/6.jpg)
J C A- LOPA J A S
J I A – E R A
Age at onset: 10 - 15 yearsBoys >> GirlsAsymmetrical oligoarthritis (lower limbs)EnthesitisAcute anterior uveitis (33 %)Association with HLA B27 (>85 %)
![Page 7: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/7.jpg)
What are the goals of therapy in rheumatic diseases?
Ultimate goal
If cure is not achievable
If control is not achievable
In all circumstances
Cure
Control
Comfort of the patient
Maintain function
![Page 8: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/8.jpg)
Does the therapy depend on the type of rheumatism?? And by consequence is it important to put a thorough diagnosis?No, to a certain point Yes, beyond that point
![Page 9: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/9.jpg)
What is the general therapeutic approach?
Medical Non medical
![Page 10: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/10.jpg)
Medical treatment
1. general treatment2. local treatment
a. eyesb. joints
![Page 11: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/11.jpg)
General medical treatment
1. anti – inflammatory
2. immunomodulatory
short term/ rapid effect/ short action/ short effect after stop
long term/ slower effect/ long action/ long effect after stop
![Page 12: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/12.jpg)
Anti-inflammatory treatment
non steroidalaspirin“classic” NSAID’sselective cox 2 inhibitors (coxib’s)
steroids
![Page 13: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/13.jpg)
Aspirin
first non steroidal anti – inflammatory drughigh dose needed 50 – 100 mg/kg/day short action 4 –6 times per day dosageside effects!
• Salicylism• Bleeding disorders• GI side effects
in low dose: anti sludge – anti thrombotic
![Page 14: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/14.jpg)
“classic” NSAID’si.e. Naproxen, Ibuprofen, Diclofenac,
Indomethacin, Piroxicam, ... 1. Indications: symptomatic
treatment of • inflammation of joints• fever of systemic origin• pain treatment
2. way of administration• oral• Rectal• IM
![Page 15: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/15.jpg)
“classic” NSAID’s
1. side effectsa. Dyspepsiab. GI ulcer – bleedingc. Fluid retention
a. Edemab. Hypertensionc. Renal insufficiency
d. Allergye. Bleeding disorder
2. relatively cheep and widely available
![Page 16: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/16.jpg)
Selective cox 2 inhibitors
mechanism of cox 2 inhibition
![Page 17: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/17.jpg)
Mechanism of action of NSAIDs
Membrane phospholipids
Arachidonic acid
NSAIDs
Gastroprotectiveprostaglandins
Proinflammatoryprostaglandins
COX-1(constitutive)
Pennisi E, Science 280:1191–1192, 1998Spangler RS, Semin Arthritis Rheum 26:435– 446, 1996
COX-2*(inducible)
COX-2 selective inhibitor
Stomach Intestine Kidney Platelet
Macrophages Synoviocytes
*COX-2 constitutively present
![Page 18: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/18.jpg)
Coxib
1. impact on side effectsthe same as “classic” NSAID’s except
GI ulcer – bleedingBleeding disorder
2. impact on effectdepending on “strength” of anti-inflammatory effect
![Page 19: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/19.jpg)
Coxib
1. indications in childrenthe same as for “classic” NSAID’s but
no proven efficacy no proven safetyno approval yet
2. expensive and not widely available yet
![Page 20: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/20.jpg)
Immunomodulatory treatment Disease modifying antirheumatic drugs = DMARDSlow acting antirheumatic drugs = SAARD
Mode of action
a. Aim to alter the immune reactionb. By that reduce the chronic aggression towards
the joint c. By that preserve the joint structure and functiond. By that preserve the quality of life
![Page 21: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/21.jpg)
DMARD
What treatments?
a. Older treatmentsb. Actual “ traditional” treatmentsc. Biologicalsd. Experimental treatments
![Page 22: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/22.jpg)
What treatments?
1. older treatments (not used anymore, but still exceptionally ....)
a. gold saltsb. levamisolec. d-penicillamin
2. “traditional” DMARD’sa. Methotrexateb. Sulphasalazinec. Hydroxychloroquined. Leflunomide
![Page 23: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/23.jpg)
Methotrexate
a. “gold standard”b. mostly indicated in polyarticular diseasec. low dose (5 mg/m²/week) versus medium
( 10 mg/m²/week) and high dose (20 mg/m²/week)
d. Oral versus IM or SC
![Page 24: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/24.jpg)
Methotrexate
e. side effectsa. Leukopeniab. liver function testsc. rare side effects (lung, bone,...)
f. monitoring
a. blood sampling every two weeks, than every four weeks, than every eight weeks
b. no liver biopsy needed!
![Page 25: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/25.jpg)
SulphasalzineEfficacy proven – Oral – 30-50 mg/kg/dayIndicated merely in oligoarticular patients and
spondyloarthropathiesSide effects
Blood cell count Liver function tests Allergy Rare side effects (hair loss, reduced male
fertility, ...)
Monitoring Blood sampling every month forst three months,
later every three months
![Page 26: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/26.jpg)
Hydroxychloroquine
a. More seldom use in JIA – Oral – 6mg/kg/dayb. Indicated in SLE and related auto-immune
diseases such as Sjögren syndromec. Side effects
a. Blood cell countb. Retinopathy
d. Monitoringa. Blood sampling every six weeks - two monthsb. Eye control 2/year
![Page 27: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/27.jpg)
Leflunomide
a. Recently developed in adultsb. Some sparse trials in children
with good resultsc. No approvald. Only trials in polyarticular JIA
![Page 28: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/28.jpg)
Biologicals
Approved
Advanced trial development
Experimental
Etanercept – Enbrel
Infliximab – RemicadeAdalimumab – Humira
CTLA4Monoclonal antibodies
![Page 29: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/29.jpg)
Treatment with ENBREL inpolyarticular-course JRA
Dose: ENBREL 0.4 mg/kg/dose SC 2X/week (maximum 25 mg/dose)
Part 1 Open-label
Months 1–3
Respondersrandomized
ENBREL (n = 69)
Placebo (n = 26)
ENBREL (n = 25)
Part 2 Double-blind
Months 4–7
All patients
ENBREL (n = 58)
Open-labelextension
Months 8–21
Lovell DJ, Giannini EH, ACR, 1999
![Page 30: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/30.jpg)
19%23%
35%44%
72%80%*
0
20
40
60
80
100
JRA 30% JRA 50% JRA 70%
Response level
Pat
ient
s (%
)
Patients achieving JRA definition of improvement after randomization
*P < 0.01
ENBREL (n = 25)Placebo (n = 26)
Lovell DJ et al, N Engl J Med 342:763–769, 2000
![Page 31: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/31.jpg)
Summary
With more than 1 year of continuous treatment withENBREL in patients with JRA
Benefits of ENBREL continue to be maintained 50/58 (86%) remain on treatment
70% demonstrate a 50% improvement in JRA Core Set Criteria
Generally well tolerated with prolonged use
No significant increase in adverse events over time
Lovell DJ, Giannini EH, ACR, 1999
![Page 32: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/32.jpg)
Biologicals
Approved
Advanced trial development
Experimental
Etanercept – Enbrel
Infliximab – RemicadeAdalimumab – Humira
CTLA4Monoclonal antibodies
![Page 33: Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium](https://reader030.vdocuments.net/reader030/viewer/2022032702/56649ce15503460f949ac434/html5/thumbnails/33.jpg)
Biologicals - monitoring
Prevention: Screening for tuberculosis Prevent contact with (some) virusses Use more often antibiotics
Side effects? Possible allergy Possible (pseudo) asthmatic reaction
(remicade) More infectious episodes
Long term side effects???? Tumor????